Noveltreat to be available in five dose strengths of 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL and 2.4 ...

By Kashish Tandon and Rishika Sadam Jan 23 (Reuters) - Sun Pharmaceutical Industries, India's top drugmaker by revenue, said ...

Sun Pharma has downplayed a rumour that it is in talks to acquire women's health specialist Organon, after a report suggested ...

By Rishika Sadam and Kashish Tandon Jan 23 (Reuters) - Indian drugmakers Sun Pharmaceutical Industries, Zydus Lifesciences ...

India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE:OGN), a ...

India's top drug maker Sun Pharmaceutical Industries has announced today the launch of a generic version of semaglutide, the ...

Sun Pharma receives DCGI approval to launch generic semaglutide injection, Noveltreat, for weight management in India.

Jan 23 () - Sun ​Pharmaceutical ‌Industries, India's ‌top drugmaker by ⁠revenue, ‌said on Friday ‍that it has ​received ‌regulatory approval to manufacture and sell ⁠generic ​semaglutide ​in India.

Sun Pharma receives DCGI approval to launch generic Wegovy semaglutide in India after patent expiry in March 2026. Check ...

Media reports this week suggested that Sun Pharma is in discussions with lenders to arrange financing for the acquisition and has submitted non-binding bids, which could value Organon at over $10 ...

India's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based ...

The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market Semaglutide ...